Evaluation of alternative strategies to optimize ketorolac transdermal delivery
- PMID: 17025245
- PMCID: PMC2750506
- DOI: 10.1208/pt070364
Evaluation of alternative strategies to optimize ketorolac transdermal delivery
Abstract
In the present study, 2 alternative strategies to optimize ketorolac transdermal delivery, namely, prodrugs (polyoxyethylene glycol ester derivatives, I-IV) and nanostructured lipid carriers (NLC) were investigated. The synthesized prodrugs were chemically stable and easily degraded to the parent drug in human plasma. Ketorolac-loaded NLC with high drug content could be successfully prepared. The obtained products formulated into gels showed a different trend of drug permeation through human stratum corneum and epidermis. Particularly, skin permeation of ester prodrugs was significantly enhanced, apart from ester IV, compared with ketorolac, while the results of drug release from NLC outlined that these carriers were ineffective in increasing ketorolac percutaneous absorption owing to a high degree of mutual interaction between the drug and carrier lipid matrix. Polyoxyethylene glycol esterification confirmed to be a suitable approach to enhance ketorolac transdermal delivery, while NLC seemed more appropriate for sustained release owing to the possible formation of a drug reservoir into the skin.
Similar articles
-
Impact of ester promoieties on transdermal delivery of ketorolac.J Pharm Sci. 2014 Mar;103(3):974-86. doi: 10.1002/jps.23888. Epub 2014 Jan 30. J Pharm Sci. 2014. PMID: 24481782
-
Synthesis and evaluation of Ketorolac ester prodrugs for transdermal delivery.J Pharm Sci. 2003 May;92(5):1008-17. doi: 10.1002/jps.10353. J Pharm Sci. 2003. PMID: 12712420
-
Ketorolac amide prodrugs for transdermal delivery: stability and in vitro rat skin permeation studies.Int J Pharm. 2005 Apr 11;293(1-2):193-202. doi: 10.1016/j.ijpharm.2005.01.002. Int J Pharm. 2005. PMID: 15778057
-
Prodrugs for transdermal drug delivery - trends and challenges.J Drug Target. 2016 Sep;24(8):671-8. doi: 10.3109/1061186X.2016.1154562. Epub 2016 Mar 17. J Drug Target. 2016. PMID: 26878159 Review.
-
Applications and limitations of lipid nanoparticles in dermal and transdermal drug delivery via the follicular route.Eur J Pharm Biopharm. 2015 Nov;97(Pt A):152-63. doi: 10.1016/j.ejpb.2015.06.020. Epub 2015 Jul 2. Eur J Pharm Biopharm. 2015. PMID: 26144664 Review.
Cited by
-
Fabrication, appraisal, and transdermal permeation of sildenafil citrate-loaded nanostructured lipid carriers versus solid lipid nanoparticles.Int J Nanomedicine. 2011;6:3195-205. doi: 10.2147/IJN.S25825. Epub 2011 Dec 6. Int J Nanomedicine. 2011. PMID: 22238508 Free PMC article.
-
Formulation and In-Vitro Characterization of pH-Responsive Semi-Interpenetrating Polymer Network Hydrogels for Controlled Release of Ketorolac Tromethamine.Gels. 2021 Oct 13;7(4):167. doi: 10.3390/gels7040167. Gels. 2021. PMID: 34698162 Free PMC article.
-
Preparation and characterization of novel nanostructured lipid carriers (NLC) and solid lipid nanoparticles (SLN) containing coenzyme Q10 as potent antioxidants and antityrosinase agents.Heliyon. 2024 May 22;10(11):e31429. doi: 10.1016/j.heliyon.2024.e31429. eCollection 2024 Jun 15. Heliyon. 2024. PMID: 38882272 Free PMC article.
-
Lipid nanocapsule-based gels for enhancement of transdermal delivery of ketorolac tromethamine.J Drug Deliv. 2011;2011:571272. doi: 10.1155/2011/571272. Epub 2011 Nov 17. J Drug Deliv. 2011. PMID: 22175029 Free PMC article.
-
Synthesis, Characterization, In-Vitro and In-Vivo Evaluation of Ketorolac Tromethamine-Loaded Hydrogels of Glutamic Acid as Controlled Release Carrier.Polymers (Basel). 2021 Oct 14;13(20):3541. doi: 10.3390/polym13203541. Polymers (Basel). 2021. PMID: 34685304 Free PMC article.
References
-
- Kokki H. Nonsteroidal anti-inflammatory drugs for postoperative pain: a focus on children. Paediatr Drugs. 2003;5:103–123. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources